타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Mosunetuzumab |
Overview Company | Epizyme, Inc. |
Overview Modality | ANTIBODY |
Overview Target | FRα |
Overview Indication | Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | novel aspects of time toxicity, demonstrate clinically meaningful differences in time burden associated with BsAbs and emphas |
Positioning Known limitation | bypassing MHC presentation |
MoA Mechanism | , pharmacokinetic properties, and key clinical efficacy and safety data from the ELM-1 and ELM-2 trials, which supported its approval by the European Medicines Agency (EMA) |
MoA Biomarker | CD20 RO% was high |
Toxicology Species | Cynomolgus monkey |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | thrombocytopenia [see Adverse Reactions (6 |
Toxicology CRS | 39% |
Clinical Safety signal | thrombocytopenia [see Adverse Reactions (6 |
Clinical Program phase | PHASE_3 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Mosunetuzumab |
Overview Company | Epizyme, Inc. |
Overview Modality | ANTIBODY |
Overview Target | FRα |
Overview Indication | Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | novel aspects of time toxicity, demonstrate clinically meaningful differences in time burden associated with BsAbs and emphas |
Positioning Known limitation | bypassing MHC presentation |
MoA Mechanism | , pharmacokinetic properties, and key clinical efficacy and safety data from the ELM-1 and ELM-2 trials, which supported its approval by the European Medicines Agency (EMA) |
MoA Biomarker | CD20 RO% was high |
Toxicology Species | Cynomolgus monkey |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | thrombocytopenia [see Adverse Reactions (6 |
Toxicology CRS | 39% |
Clinical Safety signal | thrombocytopenia [see Adverse Reactions (6 |
Clinical Program phase | PHASE_3 |
추천 비교
추천 비교